Indacaterol: Pharmacologic profile, efficacy and safety in the treatment of adults with COPD

Expert Review of Respiratory Medicine

Volumn 5, Issue 1, 2011, Pages 9-16

  Hui, Christopher Km ^a   Chung, Kian F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

bronchodilator treatment; chronic obstructive pulmonary disease; indacaterol; LABA; long acting agonist; 2 adrenoceptor agonist

Indexed keywords

BREEZHALER; INDACATEROL; ONBREZ; UNCLASSIFIED DRUG;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPNEA; EXERCISE; HUMAN; QUALITY OF LIFE; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 79952174578     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.91     Document Type: Article

References (49)

1. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364(9435), 709-721 (2004). (Pubitemid 39140629)
2. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with b-adrenergic agonists in airways disease: present and future. Eur. J. Clin. Pharmacol. 65(9), 853-871 (2009).
3. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 134(6), 1278-1286 (2008).
4. OByrne PM, Gauvreau G. Phosphodiesterase-4 inhibition in COPD. Lancet 374(9691), 665-667 (2009).
5. Frielle T, Caron MG, Lefkowitz RJ. Properties of the b 1- and b 2-adrenergic receptor subtypes revealed by molecular cloning. Clin. Chem. 35(5), 721-725 (1989). (Pubitemid 19162062)
6. Emorine LJ, Marullo S, Delavier-Klutchko C, Kaveri SV, Durieu-Trautmann O, Strosberg AD. Structure of the gene for human b 2-adrenergic receptor: expression and promoter characterization. Proc. Natl Acad. Sci. USA 84(20), 6995-6999 (1987). (Pubitemid 18017318)
7. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J. 31(4), 742-750 (2008).
8. Waldeck B. b-adrenoceptor agonists and asthma - 100 years of development. Eur. J. Pharmacol. 445(1-2), 1-12 (2002). (Pubitemid 34632676)
9. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol. 155(3), 291-299 (2008).
10. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 63(9), 831-838 (2008).
11. Beeh KM, Beier J. The short, the long and the ultra-long: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 27(3), 150-159 (2010).
12. Halpin DM, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD 6(3), 211-225 (2009).
13. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 55(4), 289-294 (2000). (Pubitemid 30248798)
14. Littner MR, Ilowite JS, Tashkin DP et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161(4 Pt 1), 1136-1142 (2000). (Pubitemid 30243820)
15. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118(5), 1294-1302 (2000).
16. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19(2), 217-224 (2002). (Pubitemid 34162820)
17. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296-1310 (2001). (Pubitemid 32804122)
18. Dahl R, Chung KF, Buhl R et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65(6), 473-479 (2010).
19. Rennard S, Bantje T, Centanni S et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Resp. Med. 102(7), 1033-1044 (2008).
20. Beier J, Chanez P, Martinot JB et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily b(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm. Pharmacol. Ther. 20(6), 740-749 (2007). (Pubitemid 47446351)
21. Bauwens O, Ninane V, Van de Maele B et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr. Med. Res. Opin. 25(2), 463-470 (2009).
22. Pavkov R, Mueller S, Fiebich K et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr. Med. Res. Opin. 26(11), 2527-2533 (2010).
23. Battram C, Charlton SJ, Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1- hydroxy-ethyl]-8- hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled b(2) adrenoceptor agonist with a 24-h duration of action. J. Pharmacol. Exp. Ther. 317(2), 762-770 (2006).
24. Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M. Effect of indacaterol, a novel long-acting b2-agonist, on isolated human bronchi. Eur. Respir. J. 29(3), 575-581 (2007). (Pubitemid 46372108)
25. Sturton RG, Trifilieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J. Pharmacol. Exp. Ther. 324(1), 270-275 (2008). (Pubitemid 350294169)
26. Sayers I, Hawley J, Stewart CE et al. Pharmacogenetic characterization of indacaterol, a novel b 2-adrenoceptor agonist. Br. J. Pharmacol. 158(1), 277-286 (2009).
27. Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A. Indacaterol, a novel inhaled b2-agonist, provides sustained 24-h bronchodilation in asthma. Eur. Respir. J. 29(5), 871-878 (2007). (Pubitemid 46711890)
28. LaForce C, Korenblat P, Osborne P, Dong F, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr. Med. Res. Opin. 25(10), 2353-2359 (2009).
29. Chuchalin AG, Tsoi AN, Richter K et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir. Med. 101(10), 2065-2075 (2007). (Pubitemid 47336870)
30. Baur F, Beattie D, Beer D et al. The identification of indacaterol as an ultralong-acting inhaled b2-adrenoceptor agonist. J. Med. Chem. 53(9), 3675-3684 (2010).
31. Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur. J. Pharm. Sci. 38(5), 533-547 (2009).
32. Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M. A cell-based assay to assess the persistence of action of agonists acting at recombinant human b(2) adrenoceptors. J. Pharmacol. Toxicol. Methods 58(3), 189-197 (2008).
33. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med. 10, 11 (2010).
34. Yang WH, Martinot JB, Pohunek P et al. Tolerability of indacaterol, a novel once-daily b2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann. Allergy Asthma Immunol. 99(6), 555-561 (2007). (Pubitemid 350308756)
35. Tarral A, Fauchoux N, Knight H. Safety and tolerability of multiple-dose indacaterol, a novel b2-agonist, in patients with mild asthma [abstract]. Eur. Respir. J. 26, 253S (2005).
36. Duvauchelle T, Elharrar B, Knight H. Single-dose indacaterol, a novel 24-h b2-agonist, is well tolerated in patients with mild asthma [abstract]. Eur. Respir. J. 26, 253S (2005).
37. Barnes PJ, Pocock SJ, Magnussen H et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther. 23(3), 165-171 (2010).
38. Beier J, Beeh KM, Brookman L, Peachey G, Hmissi A, Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm. Pharmacol. Ther. 22(6), 492-496 (2009).
39. Donohue JF, Fogarty C, Lotvall J et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 182(2), 155-162 (2010).
40. Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. DOI: 10.1183/09031936.00045810 (2010) (Epub ahead of print).
41. Beeh KM, Khindri S, Eeg M, Drollman AF. Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD. Eur. Respir. J. 34, 4357 (2009).
42. ODonnell DE, Casaburi R, Swales J, Emery C, Kramer B. Effect of indacaterol on exercise endurance in patients with moderate-to-severe COPD. Am. J. Respir. Crit. Care Med. 181, A4431 (2010).
43. Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting b2-agonist for the treatment of obstructive airways diseases. Erratum appears in Adv.Ther. 2009 6(8): 812
44. Note: Dosage error in article text. Adv.Ther. 26(7), 691-699 (2009).
45. Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr. Med. Res. Opin. 23(12), 3113-3122 (2007).
46. Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M. Efficacy and safety of indacaterol, a new 24-hour b2-agonist, in patients with asthma: a dose-ranging study. J. Asthma 45(10), 887-892 (2008).
47. Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr. Opin. Pulm. Med. 16(1), 6-12 (2010).
48. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 178(4), 332-338 (2008).
49. Roissin RR, Rabe KF, Anzueto A, Bourbeau J, Calverley P. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2008 update www.goldcopd.org (Accessed May 1 2010)